Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Up 70.0% in July

Posted by Lindsey Winhoffer on Aug 1st, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 263,890 shares, a growth of 70.0% from the June 30th total of 155,235 shares. Based on an average daily trading volume, of 201,032 shares, the days-to-cover ratio is presently 1.3 days. Currently, 6.5% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Valion Bio, Inc. Common Stock currently has an average rating of “Sell”.

View Our Latest Report on Valion Bio, Inc. Common Stock

Valion Bio, Inc. Common Stock Price Performance

VBIO stock opened at $0.31 on Friday. Valion Bio, Inc. Common Stock has a 1 year low of $0.25 and a 1 year high of $5.60. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.02 and a current ratio of 3.31. The stock’s 50 day moving average price is $0.54 and its 200 day moving average price is $0.84. The firm has a market cap of $1.29 million, a P/E ratio of -0.05 and a beta of 1.82.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($2.23) earnings per share (EPS) for the quarter.

Valion Bio, Inc. Common Stock Company Profile

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.